EQT Private Equity and Goldman Sachs to acquire Parexel for $8.5 billion
BOSTON: Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund…